Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor.
A case of myocardial infarction (MI) in a hemophilia B patient with a factor IX (FIX) inhibitor (6 BU) is described. MI occurred after two infusions of FEIBA concentrate. Unexpectedly, these infusions resulted in a neutralization of the inhibitor and a consistent plasma FIX activity which may have increased the thrombotic risks. Four days later, a psoas hematoma was suspected. At that time the inhibitor remained undetectable, allowing a therapy with purified FIX concentrates. No recurrence of thrombotic complication was observed. This is an additional illustration of the thrombotic risks associated with the use of activated prothrombin complex concentrates, especially in patients having pre-existing risk factors for thrombosis. The management of bleeding episodes in hemophilia B patients with inhibitor represents an especially difficult challenge.
Mizon
P
P
Laboratoire d'Hematologie du C.H.R.U. de Lille, France.
Goudemand
J
J
Jude
B
B
Marey
A
A
D000328:Adult; D001779:Blood Coagulation Factors / Q000009:adverse effects* / Q000627:therapeutic use; D005164:Factor IX / Q000037:antagonists & inhibitors*; D002836:Hemophilia B / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced*
D001779:Blood Coagulation Factors; D005164:Factor IX; C065655:anti-inhibitor coagulant complex